Up-regulation of hepatitis C virus replication and production by inhibition of MEK/ERK signaling. [PDF]
PLoS ONE, 2009 BACKGROUND: Viruses interact with and exploit the host cellular machinery for their multiplication and propagation. The MEK/ERK signaling pathway positively regulates replication of many RNA viruses.
Jean Ndjomou +4 more
doaj +1 more source
MEK Inhibitor-Associated Ocular Hypertension
Ocular Oncology and Pathology, 2023 <b><i>Introduction:</i></b> Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anticancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the ...
Collet, David A. +5 more
openaire +2 more sources
Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report
Drugs in Context, 2019 Systemic treatment for metastatic melanoma has advanced dramatically in recent years with an impressive increase in the rate of overall survival. The two main different strategies are targeted therapies (i.e.
Sonia Brugnara +5 more
doaj +1 more source
Immunological effects of BRAF+MEK inhibition
OncoImmunology, 2018 Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is ...
Paolo A. Ascierto, Reinhard Dummer
doaj +1 more source
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
Medicina, 2019 The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC ...
Antonio Gnoni +7 more
doaj +1 more source
mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. [PDF]
PLoS ONE, 2014 Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors.
Sean T Bailey +8 more
doaj +1 more source
Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
Platelets, 2019 The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Amanda J. Unsworth +6 more
doaj +1 more source
IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA. [PDF]
PLoS ONE, 2016 Oncogenic activation of Ras/MEK downregulates the expression of interferon regulatory factor 1 (IRF1), which is a prerequisite for oncolytic viruses to replicate in cancer cells [1].
Yumiko Komatsu +2 more
doaj +1 more source
PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK
Cell Reports, 2021 Summary: Flux through the RAF-MEK-ERK protein kinase cascade is shaped by phosphatases acting on the core components of the pathway. Despite being an established drug target and a hub for crosstalk regulation, little is known about dephosphorylation of ...
Eunice Cho +4 more
doaj +1 more source
New features in MEK retinopathy [PDF]
BMC Ophthalmology, 2018 The use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic alterations in signal transduction pathways, hence less generalised toxicity. Dabrafenib, a BRAF inhibitor and Trametinib, a MEK inhibitor are two molecularly targeted agents recently approved for treatment of advanced, unresectable ...
Pallavi Tyagi, Cynthia Santiago
openaire +3 more sources